InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company based in British Columbia, Canada, is focused on advancing a pipeline of cannabinoid-based pharmaceutical drug candidates. The company is developing a proprietary cannabinoid synthesis manufacturing system known as IntegraSyn(TM), which is designed to advance rare and lesser-known cannabinoid production to commercial levels. A recent article discussing this quotes … Continue reading InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids